Figure 2.

A. Quantal Bioassays. Each bioassay describes the effect of low dose or high dose argatroban given at various delay time points, compared to saline⁸. The group tolerance to ischemia is characterized by the ED₅₀, minutes of MCAo that renders 50% of the subjects abnormal. The ED₅₀ of each treated group is compared to the saline group after a Bonferroni correction for multiple comparisons, illustrated with curves for those subjects treated after a 3-hour delay. Both low and high dose argatroban were significantly more protective than saline (p<0.05, t-test after Bonferroni). B. Sections after 48 hours with TTC staining. Representative sections from saline and argatroban treated subjects illustrating the pale, non-metabolizing area of lesioned cerebrum reduced by argatroban. Subjects received treatment 3 hours after onset of 2-hour MCAo, and were sacrificed 48 hours later. C. Lesion volume. Mean±SD total lesion volume is shown for each group at the relevant time delays. The volume of metabolic impairment is significantly reduced (improved) by low dose argatroban given immediately or after a 1-hour delay. ** p<0.01, ANOVA with Tukey's.